Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Educational Report
  • Published:

Acute Leukemias

Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97

Abstract

In this study, the long-term outcome of 1818 patients treated in five consecutive clinical trials (the cooperative study group for childhood acute lymphoblastic leukaemia (COALL) 82, 85, 89, 92 and 97) from 24 cooperating centres in Germany is reported. The probability of event-free survival (pEFS) improved significantly from the first two trials conducted in the 1980s (COALL 82 and COALL 85) to the three trials conducted in the 1990s (COALL 89, 92 and 97) (P=0.001). Through all COALL studies, age 10 years and initial white blood cell count (WBC) 50 × 109/l and pro-B immunophenotype were of significant prognostic relevance. A refinement of risk assessment has been achieved by in vitro drug sensitivity testing in COALL 92 and 97. In patients with very sensitive leukaemic cells, therapy could be reduced without loss of efficacy. In COALL 97, a further improvement in risk stratification was gained by the molecular assessment of minimal residual disease (MRD) under treatment, which proved to have a superior prognostic effect when compared with in vitro drug sensitivity testing. Importantly, the gradual reduction in central nervous system (CNS) irradiation led to a decreased incidence of brain tumours as a second malignancy. In general, the prevention of treatment-related late effects will be one of the major issues in future studies. It remains to be shown whether prolonged infusions of anthracyclines, which have been implemented into the COALL studies after equal efficacy compared with short-time infusions was confirmed, will be associated with fewer cardiac late effects. Another way to prevent late effects may be a more refined risk assessment allowing for a reduction in cumulative treatment burden. A great challenge in the future will be to improve the overall treatment results, which very likely can only be achieved by the identification of molecularly defined subgroups to which novel, rational therapeutic strategies can be applied.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Janka GE, Winkler K, Jürgens H, Göbel U, for the COALL Study Group. Early intensification therapy in high-risk childhood acute lymphocytic leukemia: lack of benefit from high-dose methotrexate. Haematol Blood Transfus 1987; 30: 456–460.

    CAS  PubMed  Google Scholar 

  2. Jürgens H, Janka G, Ibrahim M, Tonert C, Winkler K, Göbel U . Prognostic significance of exposure to intermediate-dose methotrexate in children with standard risk ALL: the COALL 82/85 experience. Haematol Blood Transf 1992; 34: 338–342.

    Article  Google Scholar 

  3. Harms DO, Janka-Schaub GE . Co-operative study group for childhood acute lymphoblastic leukemia (COALL), long-term follow up of trials 82, 85, 89 and 92. Leukemia 2000; 14: 2234–2239.

    Article  CAS  Google Scholar 

  4. Janka-Schaub GE, Harms DO, den Boer ML, Veerman AJ, Pieters R . In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97. Klin Padiatr 1999; 211: 233–238.

    Article  CAS  Google Scholar 

  5. Harms DO, Göbel U, Spaar HJ, Graubner U, Jorch N, Gutjahr P, et al., for the COALL Study Group. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92. Blood 2003; 102: 2736–2740.

    Article  CAS  Google Scholar 

  6. Escherich G, Göbel U, Jorch N, Spaar HJ, Janka-Schaub GE . Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia. Klin Padiatr 2007; 219: 134–138.

    Article  CAS  Google Scholar 

  7. Janka GE, Göbel U, Gutjahr P, Jürgens H, Spaar HJ, Winkler K, for the COALL Study Group. Possible adverse influence of administering intrathecal methotrexate (it-MTX) non-concurrently with cranial radiotherapy (CRT) in the treatment of childhood acute lymphocytic leukemia (ALL). Med Ped Oncol 1988a; 16: 394.

    Google Scholar 

  8. Janka GE, Winkler K, Göbel U, Graubner U, Gutjahr P, Haas RJ, et al., for the COALL Study Group. Rapidly rotating combination chemotherapy in childhood acute lymphoblastic leukemia: preliminary results of a randomized comparison with conventional treatment. Leukemia 1988b; 2: 73–78.

    Google Scholar 

  9. Janka-Schaub GE, Harms D, Göbel U, Graubner U, Gutjahr P, Haas RJ, et al., for the COALL Study Group. Randomized comparison of rotational chemotherapy in high-risk acute lymphoblastic leukaemia of childhood—follow up after 9 years. Eur J Pediatr 1996; 155: 640–648.

    CAS  PubMed  Google Scholar 

  10. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  11. Andersen PK, Borch-Johnsen K, Deckert T, Green A, Hougaard P, Keiding N et al. A Cox regression model for the relative mortality and its application to diabetes mellitus survival data. Biometrics 1985; 41: 921–932.

    Article  CAS  Google Scholar 

  12. Kalbfleisch JD, Prentice RL . The Statistical Analysis of Failure Time Data, 2nd edn. Wiley Series in Probability and Statistics Wiley: New York, NY, 2002 439pp.

    Book  Google Scholar 

  13. Graubner UB, Porzig S, Jorch N, Kolb R, Wessalowski R, Escherich G et al. Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia. Ped Blood Cancer 2007; 50: 259–263.

    Article  Google Scholar 

  14. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731–1738.

    Article  CAS  Google Scholar 

  15. Conter V, Schrappe M, Arico M, Reiter A, Rizzari M, Dördelmann M et al. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukaemia with high WBC count and good response to prednisone. J Clin Oncol 1997; 15: 2786–2791.

    Article  CAS  Google Scholar 

  16. Vieira Pinheiro JP, Wenner K, Escherich G, Lanvers-Kaminsky C, Würthwein G, Janka-Schaub G et al. Serum asparaginase activities and asparagine concentrations in cerebrospinal fluid after a single infusion of 2.300 IU/m2 PEG-asparaginase in children with ALL treated according to protocol COALL 06-97. J Ped Blood Cancer 2006; 46: 18–25.

    Article  CAS  Google Scholar 

  17. Kaatsch P, Reinisch I, Spix C, Berthold F, Janka-Schaub G, Mergenthaler A et al. Case control study on the therapy of childhood cancer and the occurrence of second malignant neoplasms in Germany. Cancer Causes Control 2009; 20: 965–980.

    Article  Google Scholar 

  18. Baker KS, DeFor TE, Burns LJ, Ramsay NKC, Neglia JP, Robinson LL . New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21: 1352–1358.

    Article  Google Scholar 

  19. Löning L, Zimmermann M, Reiter A, Kaatsch P, Henze G, Riehm HJ et al. Secondary neoplasms subsequent to Berlin-Frankfurt-München therapy of acute lymphoblastic leukemia. Blood 2000; 95: 2770–2775.

    PubMed  Google Scholar 

  20. Erb N, Harms D, Janka-Schaub GE . Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol 1998; 42: 266–272.

    Article  CAS  Google Scholar 

  21. Stoneham S, Lennard L, Coen P, Lilleyman J, Saha V . Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukemia. Brit J Haematol 2003; 123: 100–102.

    Article  Google Scholar 

  22. Broxon EH, Dole M, Wong R, Laya BF, Stork L . Portal hypertension develops in a subset of children with standard risk leukemia treated with oral 6-thioguanine during maintenance therapy. Ped Blood Cancer 2005; 44: 226–231.

    Article  Google Scholar 

  23. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133–139.

    Article  CAS  Google Scholar 

  24. Berrak SG, Ewer MS, Jaffe N, Pearson P, Ried H, Zietz HA et al. Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules. Oncol Rep 2001; 8: 611–614.

    CAS  PubMed  Google Scholar 

  25. Pieters R, Huismans DR, Loonen AH, Hahlen K, van der Does-van den Berg A, van Wering ER et al. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 1991; 338: 399–403.

    Article  CAS  Google Scholar 

  26. Kaspers GJ, Pieters R, Van Zantwijk CH, De Laat PA, De Waal FC, Van Wering ER et al. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer 1991; 64: 469–474.

    Article  CAS  Google Scholar 

  27. Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R . In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 1997; 89: 2959–2965.

    CAS  PubMed  Google Scholar 

  28. Frost BM, Nygren P, Gustafsson G, Forestier E, Jonsson OG, Kanerva J et al. Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 122: 376–385.

    Article  CAS  Google Scholar 

  29. Styczynski J, Wysocki M . Is the in vitro drug resistance profile the strongest prognostic factor in childhood acute lymphoblastic leukemia? J Clin Oncol 2004; 22: 963–964.

    Article  Google Scholar 

  30. Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Korholz D et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003; 21: 3262–3268.

    Article  CAS  Google Scholar 

  31. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukaemia. European Organization for research and treatment of Cancer—Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339: 591–598.

    Article  CAS  Google Scholar 

  32. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S, et al., International BFM Study Group (I-BFM-SG). Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771–782.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We are grateful to the Fördergemeinschaft Kinderkrebs-Zentrum Hamburg for financial support. We also thank all individuals who collaborated in the designated COALL trials in the past: Dr Pongratz (Augsburg), J Otte, N Jorch (Bielefeld), HJ Spaar, T Lieber (Bremen), Dr Siegert (Dresden), U Göbel, G Janssen (Düsseldorf), JF Beck, S Weigel (Greifswald), Dr Streitberger (Heide), W Nürnberger (Idar-Oberstein), C von Klinggräff, K Westerbeck (Kiel), P Thomas, S Völpel (Krefeld), G Weißbach, U Bierbach (Leipzig), P Gutjahr (Mainz), I Althaus (Mönchengladbach), R Roos, P Klose (München-Harlaching), U Graubner, I Schmidt, Dr Haas (München, LMU), Dr Drescher, H Müller, R Kolb (Oldenburg), J Wolff, O Peters (Regensburg), J Weber (Wiesbaden) and Dr Dohrn (Wuppertal). Finally, we are indebted to M den Boer, KM Kazemir, R Pieters (Rotterdam), GJ Kaspers (Amsterdam), U zur Stadt, D Grabowski, K Michael, S Bartel and A Clodius (Hamburg) for intellectual and technical support.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding authors

Correspondence to G Escherich or M A Horstmann.

Additional information

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Escherich, G., Horstmann, M., Zimmermann, M. et al. Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97. Leukemia 24, 298–308 (2010). https://doi.org/10.1038/leu.2009.249

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2009.249

Keywords

This article is cited by

Search

Quick links